Delivery of compounds for the treatment of Parkinsons through an inhalation route
First Claim
1. A method of treating parkinsons disease comprising administering a therapeutic amount of a benzotropine, pergolide, ropinerole, anamtadine or deprenyl condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% benzotropine, pergolide, ropinerole, anamtadine or deprenyl degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antiparkinsons drugs through an inhalation route. In a method aspect of the present invention, an antiparkinsons drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiparkinsons drug on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering an antiparkinsons drug through an inhalation route is provided which comprises: a) a thin coating of a an antiparkinsons drug composition; and, b) a device for dispending said thin coating as a condensation aerosol.
89 Citations
19 Claims
-
1. A method of treating parkinsons disease comprising administering a therapeutic amount of a benzotropine, pergolide, ropinerole, anamtadine or deprenyl condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% benzotropine, pergolide, ropinerole, anamtadine or deprenyl degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
11. A method of administering benzotropine, pergolide, ropinerole, anamtadine or deprenyl to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of benzotropine, pergolide, ropinerole, anamtadine or deprenyl having less than 5% benzotropine, pergolide, ropinerole, anamtadine or deprenyl degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.
-
12. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an benzotropine, pergolide, ropinerole, anamtadine or deprenyl composition, and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
-
Specification